ArticleFrontiers in genetics2026
Novel compound heterozygous SIL1 variants associated with Marinesco-Sjögren syndrome in a Chinese family.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Marinesco-Sjögren syndrome (MSS) is a rare and disabling genetic disorder caused primarily by pathogenic variants in the SIL1 gene. SIL1 functions as a nucleotide exchange factor for the molecular chaperone BiP within the endoplasmic reticulum (ER), which is essential for protein folding. This study aims to characterize a novel SIL1 compound heterozygous pathogenic mutation and investigate its disease-causing mechanism. Methods: We determined a novel SIL1 compound heterozygous mutation information using whole exome sequencing and Sanger sequencing. RNA-seq, RT-qPCR and Western blot were employed to assess the impact of mutations on SIL1 RNA and protein levels. Immunofluorescence was used to monitor localization changes at the cellular level. Structural prediction and coimmunoprecipitation were utilized to investigate the effects of mutations on protein interactions. Results: We identified a 6-year-old girl with MSS carrying novel compound heterozygous variants in the SIL1 gene (c.570_572delCAA (p. Asn190del) and c.740C>T (p. Ala247Val)). Subsequent functional experiments revealed that the mutations show a reduction in SIL1 mRNA and protein levels. Structural prediction and coimmunoprecipitation indicate that the compound variants may be associated with the development of MSS by weakening SIL1-BiP binding. Conclusions: These findings expand the SIL1 variant spectrum and provide preliminary functional evidence that the identified variants may affect SIL1 abundance and SIL1-BiP interaction, supporting their relevance to the MSS phenotype in this family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.